Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02427's Return-on-Tangible-Equity is ranked worse than 63.87% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs HKSE:02427: -12.30
Guanze Medical Information Industry (Holding) Co (HKSE:02427) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Guanze Medical Information Industry (Holding) Co Return-on-Tangible-Equity Related Terms
Guanze Medical Information Industry (Holding) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guanze Medical Information Industry (Holding) Co Return-on-Tangible-Equity Chart
Guanze Medical Information Industry (Holding) Co Annual Data
HKSE:02427 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Guanze Medical Information Industry (Holding) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guanze Medical Information Industry (Holding) Co Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -27.42% mean?
Guanze Medical Information Industry (Holding) Co (HKSE:02427) has a Return-on-Tangible-Equity of -27.42% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. According to the industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #122 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 63.9%.
Is Guanze Medical Information Industry (Holding) Co's Return-on-Tangible-Equity too high?
Guanze Medical Information Industry (Holding) Co's current Return-on-Tangible-Equity is -27.42%. Based on the distribution chart, Guanze Medical Information Industry (Holding) Co ranks #122 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Guanze Medical Information Industry (Holding) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guanze Medical Information Industry (Holding) Co's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #122 out of 191 companies for Return-on-Tangible-Equity. This places Guanze Medical Information Industry (Holding) Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guanze Medical Information Industry (Holding) Co's current Return-on-Tangible-Equity is -27.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guanze Medical Information Industry (Holding) Co stock overvalued right now?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co (HKSE:02427) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.28, compared to a current price of HK$2.40 — trading 757.1% above its estimated fair value. The current Return-on-Tangible-Equity is -27.42%. Guanze Medical Information Industry (Holding) Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Guanze Medical Information Industry (Holding) Co (HKSE:02427), the current Return-on-Tangible-Equity is -27.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guanze Medical Information Industry (Holding) Co (HKSE:02427) Overvalued in 2026?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co stock appears to be overvalued.
The current stock price of HK$2.40 is trading 757.1% above its estimated GF Value™ of HK$0.28.
GuruFocus considers Guanze Medical Information Industry (Holding) Co to be Significantly Overvalued.
Key valuation signals for HKSE:02427:
Return-on-Tangible-Equity: -27.42%
GF Value™: HK$0.28 vs. price of HK$2.40 (757.1% above fair value)
No single metric tells the full story. See the HKSE:02427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guanze Medical Information Industry (Holding) Co Ltd is a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. The company generates the majority of its revenue from the PRC.
52GF Score
Get the complete analysis for HKSE:02427
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02427 has been successfully added to your 
